Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
medical history pertaining to diseases including abnormal blood lipids, high blood pressure, type 2 diabetes, gastroesophageal reflux disease (GERD), MASLD and obstructive sleep apnea
At 48 weeks, it reached 24.2%
With that caveat, here is what the published Phase 3 data say at peak dose, in adults with obesity and without diabetes: The roughly 6-percentage-point gap between retatrutide and tirzepatide at peak dose, sustained across more than 2,000 participants, is the data point payers and prescribers will spend the next year arguing about
We quote pricing at consultation because the right medication, dose, and duration depend on your labs and goals
We urge caution with any supplement particularly those that claim to influence GLP-1 or promote weight loss and recommend discussing any products youre considering with a licensed healthcare provider before use
WARNING This product should not be taken by those with epilepsy or seizure disorders
.svg)
